Wednesday, March 21, 2012

Georgia Demyelination Study Among Six New CDMRP Medical Treatment/Pre-Treatment Studies


The important new medical research study described in the article below is funded through the Gulf War Illness (GWI) Congressional Directed Medical Research Program (CDMRP), which must be specifically funded by Congress each year in order to continue. 

Dr. Terry's study, "Organophosphate-Related Alterations in Myelin and Axonal Transport in the Living Mammalian Brain," was funded with FY11 GWI CDMRP funds.  At the end of an arduous sifting and winnowing process, the well qualified proposals that made it to the final stage of evaluation totalled nearly $31 million.  With just a Congressional appropriation of just $8 million, only six were able to be funded, including Dr. Terry's  important study that, if successful, will help identify specific targets for treatment.
This year's appropriations process is already underway, and the Gulf War veteran community is seeking $25 million in GWI CDMRP funding for FY13, a substantial boost from FY12's hard won $10 million.  It will take substantial effort from the veterans community and allies in Congress to win this year's uphill struggle.  

-Anthony Hardie, 91outcomes.com

********


********

Nerve gas, insecticide exposure possible cause of Gulf War illness, say GHSU researchers


Monday, March 19, 2012 4:50 PM
Last updated Tuesday, March 20, 2012 6:52 AM

The memory and attention problems plaguing thousands of veterans from the first Gulf War might be caused by low-level exposure to insecticides and nerve gas, said researchers at Georgia Health Sciences University.
Dr. Alvin Terry, a professor at GHSU, and his colleague, Dr. Nathan Yanasak, are conducting a three-year study on the neurological symptoms of Gulf War illness.  JACKIE RICCIARDI/STAFF
JACKIE RICCIARDI/STAFF
Dr. Alvin Terry, a professor at GHSU, and his colleague, Dr. Nathan Yanasak, are conducting a three-year study on the neurological symptoms of Gulf War illness.


Gulf War illness could be caused by a class of chemicals known as organophosphates, which can include popular pesticides and insecticides but also the nerve gases sarin and cyclosarin.
The Department of Defense and the Central Intelligence Agency estimate 100,000 people might have been exposed to low levels of those nerve gases when troops blew up a weapons depot in Khamisiyah, Iraq, on March 10, 1991. Troops were also routinely exposed to the chemical in insecticides, said Dr. Alvin Terry, the director of the Animal Behavior Center at GHSU and professor of pharmacology and toxicology.
Terry and a colleague, Dr. Nathan Yanasak, have an $860,000, three-year grant from the DOD to study whether the chemicals can cause nerve damage in the brains of animals – in this case, mice – that could lead to memory and attention problems. They will look to see whether the insecticide chlorpyrifos, which is commonly used on crops in the U.S. and around the world – when given in low doses – might hamper the ability of the nerve cells to transport food and waste up and down the nerve.
“For it to maintain its health, it has to be able to transport things” along the axon of the nerve, Terry said. The researchers are using newer technology, such as manganese-enhanced MRI, to study that because manganese is known to be taken up and transported by nerves in the brain, he said. Researchers will also check whether the protective sheath of the nerve cells, known as myelin, is depleted by the low-level exposure, which can affect nerve firing.
“It’s probably subtle if it is there,” Terry said.
In previous work, including a study published this year, Terry and colleagues showed that “subthreshold” doses of the chemical caused memory and attention problems in rats even months later.
“Long after they have been exposed, you can still pick up on these memory deficits,” he said.
What makes that intriguing is that it is similar to problems that plague veterans with Gulf War illness, Terry said. The study in animals is is being done to find out whether that is the cause of the symptoms, which could stem from a number of other causes, such as the oil well fires that raged during the conflict and had wide exposure, Terry said.
“There’s a whole multitude of things that you could say might be a possibility,” he said. The DOD has funded research over the years into what might cause Gulf War illness, “but no one has really solved it. There have been a lot of controversies.”
His work has drawn some fire from chemical companies, but Terry said he strives for balance in his view of the chemicals.
“They have without a doubt dramatically improved farming productivity, and they have helped to get rid of vector-bone illnesses,” he said. “It’s just knowing the long-term effects; we need to be more educated on that and try to be balanced.”

Sunday, March 18, 2012

New Drug Slows Relapsing-Remitting MS


Written by Anthony Hardie, 91outcomes.com
March 18, 2012


(91outcomes.com) - A new journal article says two proof of concept Phase III clinical trials have demonstrated modest benefit from a new drug for multiple sclerosis.  Like ALS, MS it thought to be at higher rates among veterans of the 1991 Gulf War.

The article by Dr. Giancarlo Comi et al, published in the New England Journal of Medicine (NEJM, March 15, 2012), says his research team's two studies showed that oral laquinimod slows the progression of disability and reduces the effects of the relapsing-remitting form of MS.

Benefits of the once-daily therapy included reduced risk of relapse, reduced risk of confirmed disability progression, and reduced cumulative numbers of lesions and of new or enlarging lesions.

According to a U.S. News & World Report article about the study:

Multiple sclerosis (MS) is a disease that damages the outside of nerve fibers in the central nervous system, according to the National Multiple Sclerosis Society. The brain, spine and optic nerves make up the central nervous system. Symptoms of the disease can include fatigue, numbness in the limbs, balance and coordination problems, bladder or bowel dysfunction, vision problems, pain and even paralysis, according to the society.
Most patients -- about 85 percent -- have a form of MS that's called relapsing-remitting, the society has reported. That means that people have periods where the disease is very active, and at other times the disease remits. During these periods of remission, there may be complete or partial recovery of function, and the disease doesn't progress during remission, according to the society.

The study was funded by Teva Pharmaceuticals, which also developed the drug.

The UK's Multiple Sclerosis Resource Centre has more news on this drug.


GRANT ANNOUNCEMENT: FY12 Funding Opportunities for GWI Medical Research

Source:  Public Affairs Email, Congressionally Directed Medical Research Program (CDMRP), U.S. Army Medical Research & Materiel Command (USAMRMC), U.S. Department of Defense (DoD)

********************

FY12 Department of Defense Gulf War Illness Research Program Funding Opportunities
The Fiscal Year 2012 (FY12) Defense Appropriations Act provides $10 million to the Department of Defense Gulf War Illness Research Program (GWIRP) to support innovative, high-impact research into Gulf War Illness. The Department of Defense Gulf War Illness Research Program is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP). 
Please inform researchers interested in Gulf War Illness research that three award mechanisms have been released.  FY12 GWIRP program announcements and general application instructions are available at:   
http://cdmrp.army.mil/funding/gwirp.shtml
1) Investigator-Initiated Research Award - Pre-application is due April 9, 2012 Independent investigators at all academic levels are eligible to apply.
  • Supports new ideas in basic and clinical developmental research focusing on Gulf War Illness (GWI).
  • Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
  • Clinical trials are not allowed under this mechanism.
  • The maximum allowable funding for the entire period of performance is $600,000 for direct costs.
  • The maximum period of performance is 3 years.
  • More cost-effective studies not requesting the full funding amount are encouraged.
2) Innovative Treatment Evaluation Award - Pre-application is due April 9, 2012 Independent investigators at all academic levels are eligible to apply.
  • Supports exploratory or small-scale studies evaluating potential treatments not previously studied in GWI.
  • Pilot Phase II or Phase I/II trial combinations are permitted.
  • Preliminary data are not required, though proposed studies must be supported by logical rationale.
  • The maximum allowable funding for the entire period of performance is $450,000 for direct costs.
  • The maximum period of performance is 3 years.
  • More cost-effective studies not requesting the full funding amount are encouraged.
3) Clinical Trial Award - Pre-application is due April 9, 2012 Independent Investigators at all academic levels Supports larger, more definitive Phase II or III clinical trials focusing on treatments for GWI.
  • Preliminary/preclinical data are required, indicating potential substantial benefit for veterans with GWI.
  • Pilot or exploratory studies focusing on treatments lacking preclinical/preliminary data should submit to the Innovative Treatment Evaluation Award.
  • The maximum allowable funding for the entire period of performance is $1,400,000 for direct costs.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • The maximum period of performance is 4 years.
  • More cost-effective studies not requesting the full funding amount are encouraged.

ALL:  All applications must conform to the final program announcements and application instructions that are available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism can also be found by clicking the hyperlinked award mechanism titles, above. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  Funding opportunities for breast cancer, ALS, and bone marrow failure medical research are also available at this link.  
 A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline of April 9, 2012. Applications must be submitted through the federal government’s single-entry portal, Grants.gov.
Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
For additional information regarding eligibility, application submission, and questions about the program itself please contact the CDMRP helpdesk at help@CDMRP.org or call (301) 682-5507.
If you would like to request direct email messages from CDMRP, please contact CDMRP.PublicAffairs@amedd.army.mil with your email address.

UK Update: Ill Gulf War Vets Treated with "Utter Contempt", Parliament Member Agrees to Please Case of One Gulf War Vet With Defence Ministry

Source:  in-Cumbria (Cumbria, UK)
http://www.in-cumbria.com/mp-to-take-gulf-war-illness-fears-to-mod-1.935149?referrerPath=home

****************


CARLISLE MP TO TAKE CITY MAN'S GULF WAR ILLNESS FEARS TO DEFENCE MINISTRY

An MP has promised to raise the case of a former soldier suffering from Gulf War Illness with the Ministry of Defence.
Jim Heaney photo
Jim Heaney
John Stevenson has pledged to pass on the concerns of Jim Heaney after hearing how his life has been blighted by illness since the first war in Iraq.
The Carlisle veteran is pressing the Government to give greater acknowledgement to the condition so that he and others can get the testing and treatment they so desperately need.
And he has held a meeting with Mr Stevenson to see if he can take his concerns direct to the corridors of power in Whitehall.
The city Tory MP said afterwards: “We are going to try and look into the issues he has raised with us.
“Clearly, Mr Heaney has been affected. I will take up the issues he has raised with the MoD and we will wait to see what their response is.”
Like others, Mr Heaney is convinced the problems he has suffered over the past two decades have been exacerbated by the conditions he was exposed to and the vaccinations and tablets given to them before going into the battlefield.
Nerve agent pre-treatment tablets were given to protect against chemical weapons, and vaccinations to counteract biological agents.
The 40-year-old, of Wellbank Place, Longsowerby, fears troops then were used as human guinea pigs – given vaccinations, including two for anthrax in conjunction with another for whooping cough, that were not then licensed for use on humans
He wants the Government to open up independent testing and treatment for those presenting with the illness and for them to apologise for what happened. The father-of-two was pleased to have been able to speak about his case with Mr Stevenson – with a chance to remind defence chiefs that pressure for action will not disappear. He said: “It means this is going to be put before somebody so they know we are still pursuing this. We are not giving up.
“I was grateful for Mr Stevenson’s time. Whatever he can do to help is appreciated.”
Mr Heaney, who also saw active service in Bosnia and Northern Ireland as well as that in the Gulf in 1990/91, has been forced to give up work because of his illnesses.
He believes Gulf War veterans as a group have been treated with “utter contempt” with little help from the Government
“We feel each of us deserves access to proper healthcare,” he added.
Shortly after his return from the Gulf, Mr Heaney started to suffer from stress. Military medics told him it was panic or anxiety. He later discovered it was post-traumatic stress disorder.
Medication he is now on includes that to treat ailments to his back, knees, stomach, blood pressure, memory, stress and anxiety.
Mr Heaney was serving with 7 Tank Transporter Regiment – part of the Royal Corps of Transport – when he was sent to the Gulf in December 1990. He had joined the Army two years earlier and went on to become a Lance Corporal and an instructor.
The MoD say their priority is to ensure Gulf veterans who are ill receive appropriate medical care from the National Health Service.
Priority treatment is provided for those whose ill health is connected to their military service.